Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-07-30
Target enrollment:
Participant gender:
Summary
This study is a phase I, dose escalation and dose expansion study of QLS1103, to evaluate the
safety, tolerability, pharmacokinetics, and preliminary efficacy of QLS1103 in subjects with
advanced solid tumors.